Motesanib (BioDeep_00000181103)
human metabolite blood metabolite
代谢物信息卡片
化学式: C22H23N5O (373.1902508)
中文名称: 莫特塞尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1(C)CNC2=C1C=CC(=C2)N=C(O)C1=C(NCC2=CC=NC=C2)N=CC=C1
InChI: InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
描述信息
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
同义名列表
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:51098
- PubChem: 11667893
- HMDB: HMDB0254901
- DrugBank: DB05575
- ChEMBL: CHEMBL572881
- Wikipedia: Motesanib
- CAS: 453562-69-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Essam Ezzeldin, Muzaffar Iqbal, Rashad Al-Salahi, Toqa El-Nahhas. Development and validation of a UPLC-MS/MS method for determination of motesanib in plasma: Application to metabolic stability and pharmacokinetic studies in rats.
Journal of pharmaceutical and biomedical analysis.
2019 Mar; 166(?):244-251. doi:
10.1016/j.jpba.2019.01.023. [PMID: 30665192] - Yan-Xia Lv, Sen Zhong, Hexin Tang, Bin Luo, Shao-Juan Chen, Long Chen, Fei Zheng, Lei Zhang, Lu Wang, Xing-Yuan Li, Yu-Wen Yan, Ya-Mu Pan, Miao Jiang, You-En Zhang, Lei Wang, Jian-Ye Yang, Ling-Yun Guo, Shi-You Chen, Jia-Ning Wang, Jun-Ming Tang. VEGF-A and VEGF-B Coordinate the Arteriogenesis to Repair the Infarcted Heart with Vagus Nerve Stimulation.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.
2018; 48(2):433-449. doi:
10.1159/000491775. [PMID: 30016789] - Nathalie H Gosselin, Mohamad-Samer Mouksassi, Jian-Feng Lu, Cheng-Pang Hsu. Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients.
Clinical pharmacology in drug development.
2015 11; 4(6):463-72. doi:
10.1002/cpdd.196. [PMID: 27137719] - B Benjamin, M Sahu, U Bhatnagar, D Abhyankar, N R Srinivas. The observed correlation between in vivo clinical pharmacokinetic parameters and in vitro potency of VEGFR-2 inhibitors. Can this be used as a prospective guide for the development of novel compounds?.
Arzneimittel-Forschung.
2012 Apr; 62(4):194-201. doi:
10.1055/s-0031-1299772. [PMID: 22290114] - Boonchu Kulapaditharom, Vipa Boonkitticharoen, Chanika Sritara. Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma.
Journal of oncology.
2012; 2012(?):687934. doi:
10.1155/2012/687934. [PMID: 22220170] - Sergio Rutella, Franco Locatelli. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.
Clinical & developmental immunology.
2012; 2012(?):196063. doi:
10.1155/2012/196063. [PMID: 22567028] - Aneta L Zygulska, Krzysztof Krzemieniecki, Anna Sowa-Staszczak. Hypothyroidism during treatment with tyrosine kinase inhibitors.
Endokrynologia Polska.
2012; 63(4):302-6. doi:
NULL. [PMID: 22933166] - José M Gómez Sáez. Diagnostic and prognostic markers in differentiated thyroid cancer.
Current genomics.
2011 Dec; 12(8):597-608. doi:
10.2174/138920211798120826. [PMID: 22654559] - G R Blumenschein, F Kabbinavar, H Menon, T S K Mok, J Stephenson, J T Beck, K Lakshmaiah, K Reckamp, Y-J Hei, K Kracht, Y-N Sun, R Sikorski, L Schwartzberg. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2011 Sep; 22(9):2057-2067. doi:
10.1093/annonc/mdq731. [PMID: 21321086] - Mitra Niafar, Shahram Dabiri, Farshid Bozorgi, Farid Niafar, Nasrin Gholami. Metastatic medullary thyroid carcinoma: A case report.
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.
2011 Apr; 16(4):568-73. doi:
NULL. [PMID: 22091276] - Pankaj Bhargava, Murray O Robinson. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
Current oncology reports.
2011 Apr; 13(2):103-11. doi:
10.1007/s11912-011-0154-3. [PMID: 21318618] - Jian-Feng Lu, Laurent Claret, Liviawati Sutjandra, Mita Kuchimanchi, Rebeca Melara, René Bruno, Yu-Nien Sun. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
Cancer chemotherapy and pharmacology.
2010 Nov; 66(6):1151-8. doi:
10.1007/s00280-010-1456-0. [PMID: 20872145] - Michael B Bass, Steven I Sherman, Martin J Schlumberger, Martn J Schlumberger, Michael T Davis, Lisa Kivman, Huan-Mei Khoo, Kimberly H Notari, Matthew Peach, Yong-Jiang Hei, Scott D Patterson. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.
The Journal of clinical endocrinology and metabolism.
2010 Nov; 95(11):5018-27. doi:
10.1210/jc.2010-0947. [PMID: 20739388] - Martin J Schlumberger, Rossella Elisei, Lars Bastholt, Lori J Wirth, Renato G Martins, Laura D Locati, Barbara Jarzab, Furio Pacini, Chantal Daumerie, Jean-Pierre Droz, Michael J Eschenberg, Yu-Nien Sun, Todd Juan, Daniel E Stepan, Steven I Sherman. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009 Aug; 27(23):3794-801. doi:
10.1200/jco.2008.18.7815. [PMID: 19564535] - Patricia Lorusso, Elisabeth I Heath, Jesse McGreivy, Yu-Nien Sun, Rebeca Melara, Lucy Yan, Lisa Malburg, Megan Ingram, Jeffrey Wiezorek, Li Chen, Mary Jo Pilat. Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
Investigational new drugs.
2008 Oct; 26(5):455-62. doi:
10.1007/s10637-008-9144-1. [PMID: 18574557]